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in  addition  to  the  well-known  components  of  the  im-
mune  response  to  inflammation,  other  inflammatory 
pathways have been recently invoked. Among these, an 
inflammatory molecule called high mobility group box 
1 (hMgB1) can be highlighted, which is an evolution-
ary ancient protein that serves predominately as a DnA-
binding protein with “alarmin” activity. yang et al. 1 used 
the term “alarmin” to indicate numerous granule-derived 
mediators that rapidly galvanize antigen-presenting cells 
(APCs) and trigger innate and adaptive immune respons-
es. They represent the first host response to exogenous 
(infections)  and  endogenous  (injuries)  danger  signals. 
Alarmins have the dual capacity to recruit and activate 
inflammatory cells including dendritic cells (DCs), using 
giα-protein-coupled receptor(s) (giPCr) and activating 
receptor(s), respectively. Alarmins are usually constitu-
tively present in cells, such as leukocytes and epithelial 
cells, as components of the granules, cytoplasm and nu-
cleus. They are endogenous peptides that are released in 
host defence against danger signals, and therefore, can be 
considered as a subset of damage associated molecular 
patterns (DAMPs) 1. hMgB1 is ubiquitously expressed 
in the nuclear compartment of eukaryotic cells function-
ing as a transcriptional regulator via interaction of its A-
box and B-box subunits with DnA. Therefore, quiescent 
macrophages/monocytes constitutively express hMgB1 
and maintain an intracellular “pool” of hMgB1 predomi-
nantly in the nucleus. in the late 1990’s, Wang et al. 2 re-
ported that extracellular hMgB1 is actively released as a 
late mediator of inflammation in sepsis by activated mac-
rophages/monocytes. After  stimulation  with  exogenous 
bacterial products such as endotoxin, or with endogenous 
pro-inflammatory cytokines such as TnF-α, il-1β and 
iFn-γ, cultures of macrophages, monocytes, and pitui-
cytes actively release hMgB1 in a time- and dose-de-
pendent manner. in addition to its active release, hMgB1 
can also be released passively from necrotic or damaged 
cells.  however,  hMgB1  is  not  released  by  apoptotic 
cells, which degrade without setting off an inflammatory 
response. Therefore, hMgB1 is extracellularly released 
as a result of loss of membrane integrity upon necrosis of 
nucleated cells (including neutrophils) and by activated 
leukocytes via an initial acetylation on many of the 43 
lysine residues of hMgB1 in the nucleus. As an extracel-
lular protein, hMgB1 has pleomorphic effects including 
activation of nF-κB, diffuse endothelial activation, hepa-
tocellulary injury, epithelial leak, and systemic activation 
of inflammatory cells 3. hMgB1 activates inflammatory 
cells through interactions between the receptor for ad-
vanced glycation end-products (rAgE) or toll-like recep-
tor (Tlr)-2 and -4. This occurs through the coordinated 
release from stimulated cells following acetylation of nu-
clear hMgB1, leading to cytoplasmic translocation and 
export via secretory vesicles. once released, hMgB1 has 
been reported to have pro-inflammatory effects, and high 
levels have been associated with human or experimental 
models of sepsis 2, haemorrhagic shock, rheumatoid ar-
thritis 4, systemic lupus erythematosus 5 and within the air-
ways during ventilator-induced lung injury 6. recently 7, 
hMgB1 has been studied for its potential impact in cystic 
fibrosis lung disease.
Extracellular  hMgB1  binds  to  cell  surface  receptors 
such as rAgE, Tlr-2 and Tlr-4, and possibly to yet 
unknown receptors. receptor binding leads to activation 
of the transcription factors nF-κB, inducing transcription 
of multiple pro-inflammatory genes. Upon (co-)activation 
with  hMgB1,  macrophages  produce  pro-inflammatory 
cytokines such as TnF-α, il-1β, il-6, il-8, macrophage 
inflammatory protein-1α and MiP-2β 8.
hMgB1 acts as an alarmin because it induces both migra-
tion and activation of DCs and enhances antigen-specific 
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protein is chemotactic for immature DCs and can contrib-
ute directly to local recruitment of DCs.
numerous studies have shown the participation of alarm-
ins such as hMgB1 in the development of inflammation 
and the immune response. The levels of neutrophil-derived 
alarmins are high under many inflammatory conditions, 
whereas blockade of some of these mediators have been 
shown to ameliorate the manifestations of acute inflamma-
tory reactions. There is increasing evidence that hMgB1 
contributes to the pathogenesis of chronic inflammatory 
and autoimmune disease due to its pro-inflammatory and 
immunostimulatory properties. intratracheal administra-
tion of hMgB1 induces lung neutrophil infiltration, local 
production of pro-inflammatory cytokines and acute lung 
injury 10. After viral infection, hMgB1 may be actively or 
passively released by infected cells producing an inflam-
matory response driven both by infected cells and neigh-
bouring innate immune cells. hMgB1 released by tumour 
tissues might contribute to tumour progression related to 
pro-inflammatory and pro-angiogenetic effects.
The recent discovery of hMgB1 as a critical mediator of 
inflammation has stimulated an increasing interest in the 
field of inflammation research. These important new find-
ings have also suggested different perspectives in the EnT 
field where further investigation is needed to identify pos-
sible new therapies for viral/bacterial infection and other 
inflammatory diseases of the upper airways.
our research group, in collaboration with the “EnT gro-
mo institute” in Buffalo (USA) and the “Tongren general 
hospital” of Beijing (China), is examining the results of a 
research projected to offer a quantitative evaluation of this 
protein observed in the mucosa of patients suffering from 
allergic and vasomotor rhinitis, rhinosinusitis and nasal 
polyposis.
in light of the more recent knowledge and technologies, 
this study has been structured following specific method-
ologies.
Moreover, the possible application of certain substances 
capable  of  inhibiting  the  pro-inflammatory  effects  of 
hMgB1 is also under investigation. The anti-inflamma-
tory and immunosuppressive effects could be obtained 
through three main mechanisms: inhibiting the release; 
blocking  protein  receptors  (rAgE,  Tlr2,  Tlr4  and 
Tlr9) through direct receptor antagonism; or inactivat-
ing hMgB1 protein after its release from the necrotic 
cells through a scavenger mechanism.
These studies were projected according to two main lines 
of research: the first is aimed to define a suitable qualitative 
and quantitative determination methodology. in this view, 
two main methodological approaches should be consid-
ered: 1) immunohistochemical staining for hMgB1 and 
other inflammatory cytokines (TnF-α, il-1βF) followed 
by a semiquantitative analysis of cells staining positive 
for the protein of interest; 2) immunofluorescence stain-
ing and confocal analysis of intra/extracellular distribu-
tion of the hMgB1 protein.
The second research line has the aim of better understand-
ing the mechanism of action of substances involved in re-
duced levels of the protein and to determine their clinical 
relevance, compliance, cost/benefit ratio and safety pro-
file.
it seems important to suggest that clinical and experimen-
tal researches on these topics should be continued, with 
the aim of reducing issues due to diseases which are perti-
nence to the EnT field, and which are now recognized as 
“Social Diseases”
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